Thelansis’s "Phelan-McDermid Syndrome (PMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential 22q13 deletion syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Phelan-McDermid Syndrome (PMS), or 22q13 deletion syndrome, is a rare genetic disorder caused by a deletion or structural change at the terminal end of chromosome 22 or a pathogenic variant in the SHANK3 gene. This genetic alteration affects brain development and functioning, leading to a wide range of medical, intellectual, and behavioral challenges. Symptoms often include neonatal hypotonia, developmental delays, absent or severely delayed speech, intellectual disability, and autism spectrum disorder or autistic-like traits. Additional features may include seizures, motor delays, sleep disturbances, gastrointestinal issues, and cardiac abnormalities. The severity and indication of symptoms vary widely among individuals. While there is no cure for PMS, management focuses on addressing specific symptoms through therapies and medications.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Phelan-McDermid Syndrome (PMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report
Our team will get in touch with you shortly about the Phelan-McDermid Syndrome (PMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report.